Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions: Omadacycline Oral Tablet, Placebo; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 17
States / cities: Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more

Conditions: Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions: Lactiplantibacillus plantarum, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Years to 45 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV-1-infection
Interventions: Saline, Lefitolimod, 3BNC117 and 10-1074; Drug
Lead sponsor: University of Aarhus; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tourette Syndrome
Interventions: levodopa solution 2mg/ml for i.v. use, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Peripheral Arterial Disease
Interventions: atorvastatin, ascorbic acid, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: No Evidence of Disease, Prostate Carcinoma
Interventions: Selenium, Placebo, Laboratory Biomarker Analysis, Pharmacological Study, Methylselenocysteine; Dietary Supplement · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • Buffalo, New York • Nashville, Tennessee

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Varicose Veins
Interventions: Polidocanol injectable foam (PEM), Placebo Vehicle; Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 20
States / cities: Laguna Hills, California • San Diego, California • Washington D.C., District of Columbia + 17 more

Conditions: Plaque Psoriasis
Interventions: DC-806, Placebo; Drug · Other
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: Fountain Valley, California • Santa Monica, California • Coral Gables, Florida + 10 more

Conditions: Obesity, Overweight, Chronic Weight Management
Interventions: Aleniglipron, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 3,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 64 more

Conditions: Heart Failure, Congestive, Chronic Heart Failure, Depression
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 45 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Thromboembolism
Interventions: Warfarin, Dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more

Conditions: Probiotics
Interventions: Lactic acid bacteria and bifidobacteria, Placebo; Dietary Supplement · Other
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Healthy
Interventions: ACU-4429, matching placebo; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Nandrolone decanoate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: Schizophrenia
Interventions: NSA-789 at 2 different doses; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: NS-229, Placebo; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more

Conditions: Alzheimer Disease
Interventions: AVE1625; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Restrictive Burn Scars of Joint Area
Interventions: Autologous Human Fibroblasts (Isolagen TherapyTM), Placebo; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • East Meadow, New York • Galveston, Texas

Conditions: Delayed Onset Muscle Soreness
Interventions: Loxoprofen Pain Patch, Placebo Patch, No Treatment; Drug
Lead sponsor: Lead Chemical Co., Ltd.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Osteoporosis, Hypomagnesemia
Interventions: EffCaMgCit, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Social Anxiety in Autistic Adults
Interventions: Placebo, Midomafetamine HCl, Therapy; Drug · Behavioral
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Torrance, California

Conditions: Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions: Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 21,379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 250
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more

Conditions: Arthroscopy
Interventions: Celecoxib, Placebo; Drug · Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 9
States / cities: Phoenix, Arizona • St. Petersburg, Florida • Baltimore, Maryland + 6 more

Search by objective public record fields.

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Reducing Innate Inflammation in New Onset Type 1 Diabetes

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)

Clinical Utility of Endothelial Dysfunction in PAD

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

The Effects of Probiotic Supplementation on Markers of Muscle Damage and Performance Following Exercise Induced Muscle Damage

Safety and Tolerability of ACU-4429

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery